Anti-Suicide Drugs Market 2019: New Product Like Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., Lundbeck A/S, NeuroRx

NeuroRx Pharma has developed a novel anti-suicidal product Cyclurad (D-cycloserine and Lurasidone) which is indicated for Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression. The estimated commercialization of the drug post-2020 is expected to be a major breakthrough innovation for the anti-suicide drugs market. Moreover, introduction of other such novel drugs for suicide would augment the anti-suicide market growth. People with major depressive disorder and risk for suicide would greatly benefit from such novel drug therapies.

Free Request Sample Copy of This Report: www.coherentmarketinsights.com/insight/request-sample/10

Off-label use of these drugs for suicidal ideation has been a practice for years, as there are no approved anti-suicide specific drug yet. However, the dynamics is expected to change in the following few years with the launch of first oral therapeutic drug for acute suicidal ideation. This would disrupt the use of antidepressants and anti-psychotic drugs for the treatment of suicidal tendencies. Suicidal incidences are high in low and middle income countries according to the WHO 2016 statistics.

Although the incidence in Asia, East Africa, and Eastern European region is high, these regions lag in terms of availability of affordable medications and healthcare facilities. Therefore developed economies of North America and Western Europe are key target regions for manufacturers in the near future. Rampant economic growth and projected strengthening of the healthcare infrastructure in emerging economies in towards the first half of the following decade is projected to shift the focus of these companies towards highly populous regions of India and China in the long run.

According to the World Health Organization (WHO), suicide accounted for 1.4% of the total deaths worldwide in 2012, accounting for around 800 thousand deaths each year. Russia, India, Republic of Korea, Guyana, Lithuania, Sri Lanka, Hungary, Kazakhstan, and Japan are among the nations with high suicidal rates as per the WHO 2012 data. Emerging nations therefore possess immense opportunity for anti-suicidal drugs.

Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/10

Detailed Segmentation:

Global Anti-Suicide Drugs Market, By Chemistry Type:
Anti-Depressants and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Global Anti-Suicide Drugs Market, By Geography:
North America
U.S.
U.S. Anti-Suicide Drugs Market, By Chemistry Type:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Canada
Canada Anti-Suicide Drugs Market, By Chemistry Type:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog
Europe
U.K.
U.K Anti-Suicide Drugs Market, By Chemistry Type:
Anti-Depressant and Anti-Anxiety Drugs
Anti-Psychotic Drugs
NMDA Antagonist
Antibiotic Analog

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/10

Major players operating in the global anti-suicide drugs market include Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H. Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.